Story perspectives

Daily Aspirin Cuts Colorectal Cancer Recurrence by 55%

9/19/2025

50 5

Summary

Story summary

A Swedish study revealed that daily low-dose aspirin can lower colorectal cancer recurrence by 55% in patients with specific genetic mutations.
Over 3,500 participants from Sweden, Norway, Denmark, and Finland, who had tumor removal surgery, took part in the trial.
Patients with PIK3CA mutations received either 160mg of aspirin or a placebo for three years.
Researchers found that aspirin may reduce inflammation and disrupt tumor growth pathways.
Serious side effects affected 16.8% of aspirin users, prompting experts to recommend genetic testing for potential aspirin therapy candidates.

1 of 1

Story summary

A Swedish study revealed that daily low-dose aspirin can lower colorectal cancer recurrence by 55% in patients with specific genetic mutations.
Over 3,500 participants from Sweden, Norway, Denmark, and Finland, who had tumor removal surgery, took part in the trial.
Patients with PIK3CA mutations received either 160mg of aspirin or a placebo for three years.
Researchers found that aspirin may reduce inflammation and disrupt tumor growth pathways.
Serious side effects affected 16.8% of aspirin users, prompting experts to recommend genetic testing for potential aspirin therapy candidates.